XLO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Stats
Dagens volum	375 405
Gjennomsnittsvolum	1.22M
Markedsverdi	38.39M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $-0.300 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.370
ATR14	$0.00800 (0.78%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Gilead Sciences, Inc.	Buy	485 250	Common Stock
2024-04-02	Gilead Sciences, Inc.	Buy	3 882 450	Prefunded Warrants (right to buy)
2024-03-27	Gilead Sciences, Inc.	Sell	0	Common Stock
2024-02-08	Atlas Venture Fund Xi, L.p.	Sell	733	Common Stock
2024-02-08	Atlas Venture Fund Xi, L.p.	Sell	267	Common Stock

INSIDER POWER
91.69
Last 95 transactions
Buy: 18 066 351 \| Sell: 51 747 162

Volum Korrelasjon

Lang: 0.03 (neutral)

Kort: -0.80 (strong negative)

Signal:(38.412) Neutral

Xilio Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
AMRB	0.872
OTRK	0.864
NEON	0.858
SHYF	0.843
PPTA	0.841
POET	0.825
UBFO	0.825
LWAC	0.82
PBPB	0.82
NVCN	0.819

10 Mest negative korrelasjoner
TUEM	-0.819
STAB	-0.818
CFV	-0.812
AHPI	-0.802

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Xilio Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.17
( neutral )

-0.21
( neutral )

0.00
( neutral )

-0.26
( neutral )

Xilio Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2023
Omsetning:	$0
Bruttogevinst:	$-1.90M (0.00 %)
EPS:	$-2.78

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.85M (0.00 %)
EPS:	$-3.19

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-13.52

Financial Reports:

No articles found.

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.